Grade 1 to 2 diarrhea occurred in 73% of the patients in the abemaciclib group and in 24.2% of the placebo group.
Anti-diarrheal medicine effectively managed this symptom in most cases, according to the study report.Grade 3 diarrhea occurred in 13.4% of patients in the abemaciclib group and 0.4% of patients in the placebo group.
No grade 4 diarrhea was reported.Grade 3 to 4 neutropenia occurred in 25.5% of patients in the abemaciclib group and 1.7% of patients in the placebo group.
Febrile neutropenia was reported in six patients in the abemaciclib arm.
The primary end point (investigator-assessed PFS) was met, with median duration of follow-up of 19.5 months.